Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01124851 | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness | PHASE1 | COMPLETED | 36 | — | — | Aug 1, 2010 | Apr 1, 2011 | Jul 4, 2011 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days |
| Arm 2 | EXPERIMENTAL | ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days |
| Arm 3 | EXPERIMENTAL | ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days |
| Name | Type | Description |
|---|---|---|
| ABT-652 | DRUG | See arm description for details |
| Placebo | DRUG | See arm description for details |
Inclusion Criteria * Has current diagnosis of an excessive daytime sleepiness disorder, including narcolepsy, idiopathic hypersomnia, and obstructive sleep apnea * Age 18 to 60 years Exclusion Criteria * Has significant suicidal ideation * Has a history of substance abuse * Has a history of a certa...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 3 | PHASE3 | Tasimelteon |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan , Astra-Zeneca |
| Unity Health Toronto | UBX | 1 | PHASE2 | Lemborexant |
| ResMed Inc. | RMD | 1 | NA | Undisclosed |
| IQVIA Holdings Inc | IQV | 1 | — | Daridorexant, Non-orexin receptor antagonist medications for insomnia |